Astrazeneca PLC Company Profile (NYSE:AZN)

About Astrazeneca PLC

Astrazeneca PLC logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: AZN
  • CUSIP:
Key Metrics:
  • Previous Close: $29.01
  • 50 Day Moving Average: $28.23
  • 200 Day Moving Average: $29.78
  • 52-Week Range: $25.55 - $35.04
  • Trailing P/E Ratio: 20.96
  • Foreward P/E Ratio: 14.68
  • P/E Growth: 2.06
  • Market Cap: $73.17B
  • Outstanding Shares: 2,530,000,000
  • Beta: 0.77
  • Net Margins: 15.21%
  • Return on Equity: 34.30%
  • Return on Assets: 8.57%
  • Debt-to-Equity Ratio: 0.87%
  • Current Ratio: 0.87%
  • Quick Ratio: 0.72%
Additional Links:
Companies Related to Astrazeneca PLC:

Analyst Ratings

Consensus Ratings for Astrazeneca PLC (NYSE:AZN) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $35.68 (23.37% upside)

Analysts' Ratings History for Astrazeneca PLC (NYSE:AZN)
DateFirmActionRatingPrice TargetDetails
2/21/2017Berenberg BankReiterated RatingBuyView Rating Details
1/21/2017Leerink SwannReiterated RatingOutperformView Rating Details
12/13/2016J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
11/25/2016Liberum CapitalUpgradeHold -> BuyView Rating Details
11/11/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
11/11/2016Beaufort SecuritiesReiterated RatingHoldView Rating Details
11/10/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
11/10/2016Bank of America CorpReiterated RatingBuy$41.37View Rating Details
11/10/2016Shore CapitalReiterated RatingHoldView Rating Details
11/7/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
10/5/2016Goldman Sachs Group, Inc. (The)Reiterated RatingSellView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightView Rating Details
9/13/2016BNP ParibasDowngradeOutperform -> NeutralView Rating Details
9/12/2016Jefferies Group LLCUpgradeHold -> BuyView Rating Details
8/29/2016ArgusUpgradeHold -> Buy$38.00View Rating Details
2/28/2016Drexel HamiltonInitiated CoverageBuyView Rating Details
2/8/2016HSBC Holdings plcDowngradeBuy -> HoldView Rating Details
2/5/2016Sanford C. BernsteinLower Price Target$34.00 -> $32.00View Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> Top PickView Rating Details
1/19/2016Barclays PLCUpgradeUnderweight -> Equal Weight$44.00 -> $50.00View Rating Details
1/13/2016Credit Suisse GroupReiterated RatingUnderperformView Rating Details
12/30/2015Morgan StanleyReiterated RatingBuyView Rating Details
11/2/2015Nordea Equity ResearchDowngradeBuy -> HoldView Rating Details
9/18/2015Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details
7/31/2015S&P Equity ResearchUpgradeBuy$38.00View Rating Details
7/31/2015SwedbankUpgradeNeutral -> BuyView Rating Details
6/2/2015Kepler Capital MarketsReiterated RatingReduceView Rating Details
4/15/2015Societe GeneraleInitiated CoverageBuyView Rating Details
(Data available from 2/23/2015 forward)


Earnings History for Astrazeneca PLC (NYSE:AZN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/2/2017Q416$0.59$1.21$5.43 billion$5.59 billionViewListenView Earnings Details
11/10/2016Q316$0.74$1.32$5.95 billion$5.70 billionViewN/AView Earnings Details
7/28/2016Q216$0.76$0.83$5.56 billion$5.60 billionViewListenView Earnings Details
4/29/2016Q1$0.60$0.51$5.96 billion$6.12 billionViewListenView Earnings Details
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details
7/30/2015Q2$1.08$1.21$6.02 billion$5.84 billionViewListenView Earnings Details
4/24/2015Q1$1.07$1.08$5.87 billion$6.06 billionViewN/AView Earnings Details
2/5/2015Q314$0.85$0.76$6.68 billion$6.68 billionViewN/AView Earnings Details
11/6/2014Q3$1.04$1.05$6.44 billion$6.54 billionViewN/AView Earnings Details
7/31/2014Q214$1.09$1.30$6.24 billion$6.45 billionViewN/AView Earnings Details
4/24/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details
4/25/2013$1.36$1.41$6.54 billion$6.39 billionViewN/AView Earnings Details
1/31/2013Q412$1.37$1.56$7.17 billion$7.28 billionViewN/AView Earnings Details
10/25/2012$1.44$1.51ViewN/AView Earnings Details
7/26/2012$1.38$1.53ViewN/AView Earnings Details
4/26/2012$1.73$1.81ViewN/AView Earnings Details
2/2/2012$1.57$1.61ViewN/AView Earnings Details
10/27/2011$1.64$1.71ViewN/AView Earnings Details
7/28/2011$1.74$1.53ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Astrazeneca PLC (NYSE:AZN)
Current Year EPS Consensus Estimate: $1.82 EPS
Next Year EPS Consensus Estimate: $1.97 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.53$1.01$0.77
Q2 20162$0.40$0.45$0.43
Q3 20162$0.47$0.51$0.49
Q4 20162$0.47$0.60$0.54
Q1 20171$0.32$0.32$0.32
Q2 20171$0.42$0.42$0.42
Q3 20171$0.38$0.38$0.38
Q4 20171$0.63$0.63$0.63
(Data provided by Zacks Investment Research)


Current Dividend Information for Astrazeneca PLC (NYSE:AZN)
Annual Dividend:$1.37
Dividend Yield:4.74%
Dividend Growth:-21.20% (3 Year Average)
Payout Ratio:49.64% (Based on Trailing 12 Months of Earnings)
75.27% (Based on Current Year Consensus EPS Estimate)
69.54% (Based on Next Year Consensus EPS Estimate)

Dividend History for Astrazeneca PLC (NYSE:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Astrazeneca PLC (NYSE:AZN)
No insider trades for this company have been tracked by


Latest Headlines for Astrazeneca PLC (NYSE:AZN)
DateHeadline logoFitch Affirms Astrazeneca at 'A'; Stable Outlook (NYSE:AZN) - February 23 at 1:51 AM
News IconAstraZeneca plc (AZN) Given New GBX 5450 Price Target at Berenberg Bank (NYSE:AZN) - February 23 at 1:51 AM
News IconBeaufort Securities Reiterates "Hold" Rating for AstraZeneca plc (AZN) (NYSE:AZN) - February 23 at 1:51 AM
News IconAstrazeneca PLC's (AZN) "Buy" Rating Reaffirmed at Berenberg Bank (NYSE:AZN) - February 23 at 1:51 AM logoMerck & Co.’s Segment-Wise Revenues for 4Q16 (NYSE:AZN) - February 22 at 3:47 PM logoKeytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug (NYSE:AZN) - February 22 at 3:47 PM logoAnalyst Activity – Berenberg Bank Reiterates Buy on Astrazeneca PLC (NYSE:AZN) (NYSE:AZN) - February 22 at 11:53 AM
News IconAstraZeneca plc (AZN) Stock Rating Reaffirmed by JP Morgan Chase & Co (NYSE:AZN) - February 22 at 11:53 AM logoAnalyst: Buy AstraZeneca On The Turnaround Story (NYSE:AZN) - February 22 at 11:53 AM
News IconEstimating the intrinsic value of AstraZeneca PLC (LSE:AZN ... - Simply Wall St (NYSE:AZN) - February 21 at 3:28 PM logoAnalyst Activity – Berenberg Bank Reiterates Buy on Astrazeneca PLC (NYSE:AZN) - Market Exclusive (NYSE:AZN) - February 21 at 10:55 AM logoThe Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson (NYSE:AZN) - February 21 at 10:55 AM logo4:16 am AstraZeneca reports Phase III trial for Lynparza meets primary endpoint (NYSE:AZN) - February 20 at 3:42 PM logoSanofi’s Unique Foothold in Diabetes and Cardiovascular (NYSE:AZN) - February 20 at 9:33 AM
News IconWhich insiders are trading AstraZeneca PLC (AZN)? (NYSE:AZN) - February 18 at 3:42 PM logo[$$] AstraZeneca boosted by positive breast cancer trial (NYSE:AZN) - February 18 at 3:42 PM logoEuropean Benchmarks Fall, But London Bucks Trend on Takeover Activity (NYSE:AZN) - February 18 at 3:42 PM
News IconTechnical Study: Following Indicators for AstraZeneca PLC (AZN) - Baldwin Journal (NYSE:AZN) - February 17 at 3:16 PM logoAstraZeneca breast cancer drug trial positive (NYSE:AZN) - February 17 at 10:25 AM
News IconAstraZeneca Trial For Breast Cancer Treatment Shows Positive Results (NYSE:AZN) - February 17 at 10:25 AM logoAstraZeneca reveals positive breast cancer treatment trial results; Woodford adds to holding (NYSE:AZN) - February 17 at 10:25 AM logoAstraZeneca : Lynparza meets main goal in breast cancer study (NYSE:AZN) - February 17 at 10:25 AM
News IconAstraZeneca plc (AZN) Rating Reiterated by Shore Capital (NYSE:AZN) - February 17 at 10:25 AM logoBritain's FTSE set for week of modest gains, pharmas lead (NYSE:AZN) - February 17 at 10:25 AM logoLYNPARZA™ (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer (NYSE:AZN) - February 17 at 10:25 AM logoAstraZeneca Stock Rises On Successful Breast Cancer Drug Trial (NYSE:AZN) - February 17 at 10:25 AM logoAstraZeneca's Lynparza meets main goal in breast cancer study (NYSE:AZN) - February 17 at 10:25 AM
News IconTrading Watch: Indicators in Review for AstraZeneca PLC (AZN) - SKV News (NYSE:AZN) - February 16 at 3:50 PM logoTop AstraZeneca shareholder Woodford adds to stake, bullish on outlook (NYSE:AZN) - February 16 at 3:50 PM logoAstraZeneca to Get $130 Million Payment as Psoriasis Drug Siliq Gets FDA Approval (NYSE:AZN) - February 16 at 8:43 AM logoAnalyst Activity – Shore Capital Reiterates Sell on AstraZeneca plc (LON:AZN) (NYSE:AZN) - February 16 at 8:43 AM
News IconThe AstraZeneca plc (AZN) Receives Equal weight Rating from the Barclays PLC (NYSE:AZN) - February 16 at 8:43 AM
News IconAstraZeneca plc (AZN) Price Target Cut to GBX 5100 (NYSE:AZN) - February 16 at 8:43 AM logoEuropean stocks stage pullback (NYSE:AZN) - February 16 at 8:43 AM logoETFs with exposure to AstraZeneca Plc : February 14, 2017 (NYSE:AZN) - February 14 at 3:22 PM logoEx-Dividend Reminder: Duke Energy, Cheniere Energy Partners and AstraZeneca (NYSE:AZN) - February 13 at 4:18 PM logoA FTSE 100 giant with 20% upside to consider (NYSE:AZN) - February 11 at 2:25 AM logoSanofi -- Moody's: Pipelines are biggest credit quality hope for Europe's Pharma sector in 2017 (NYSE:AZN) - February 10 at 4:21 PM
News IconStock Check: Reviewing the Numbers for AstraZeneca PLC (AZN.L) - Baldwin Journal (NYSE:AZN) - February 9 at 3:55 PM logoBladder Cancer Drug Competition Ramps Up (NYSE:AZN) - February 9 at 3:55 PM
News IconStock Levels in Review for AstraZeneca PLC (AZN) - Benton Bulletin (NYSE:AZN) - February 8 at 3:55 PM logoAstraZeneca Plc :AZN-US: Earnings Analysis: 2016 By the Numbers : February 7, 2017 (NYSE:AZN) - February 7 at 4:42 PM
News IconRead this before buying AstraZeneca PLC (LSE:AZN) for its upcoming £1.5 dividend (NYSE:AZN) - February 6 at 8:54 PM
News IconQuarterly Financial Watch for Astrazeneca PLC (NYSE:AZN) - The Newburgh Press (NYSE:AZN) - February 6 at 3:48 PM logoAstraZeneca Plc :AZN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017 (NYSE:AZN) - February 6 at 3:48 PM logoDodge & Cox Comments on AstraZeneca (NYSE:AZN) - February 6 at 3:48 PM
News IconLeading stocks in today’s market: AstraZeneca PLC (NYSE:AZN) (NYSE:AZN) - February 4 at 8:58 PM logoAstraZeneca Shrugs Off Bristol-Myers' Setback; Crushes Q4 Views (NYSE:AZN) - February 3 at 3:55 PM logoAstraZeneca flags falling profit while awaits key drug data (NYSE:AZN) - February 2 at 8:52 PM logoAstraZeneca stands by 2023 sales above $40 billion at today's FX (NYSE:AZN) - February 2 at 8:52 PM


What is Astrazeneca PLC's stock symbol?

Astrazeneca PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does Astrazeneca PLC pay dividends? What is the dividend yield for Astrazeneca PLC?

Astrazeneca PLC announced a semiannual dividend on Friday, February 3rd. Stockholders of record on Friday, February 17th will be given a dividend of $0.95 per share on Monday, March 20th. This represents a dividend yield of 6.81%. The ex-dividend date is Wednesday, February 15th.

When did Astrazeneca PLC's stock split? How did Astrazeneca PLC's stock split work?

Astrazeneca PLC shares split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were distributed to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of Astrazeneca PLC stock prior to the split would have 200 shares after the split.

Where is Astrazeneca PLC's stock going? Where will Astrazeneca PLC's stock price be in 2017?

16 analysts have issued 12-month price objectives for Astrazeneca PLC's shares. Their forecasts range from $29.35 to $41.37. On average, they anticipate Astrazeneca PLC's stock price to reach $35.68 in the next year.

Who owns Astrazeneca PLC stock?

Astrazeneca PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (0.22%), Viking Global Investors LP (0.11%), Federated Investors Inc. PA (0.10%), Capital Guardian Trust Co. (0.10%), Dimensional Fund Advisors LP (0.08%) and Franklin Resources Inc. (0.07%).

Who sold Astrazeneca PLC stock? Who is selling Astrazeneca PLC stock?

Astrazeneca PLC's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Federated Investors Inc. PA, Viking Global Investors LP, Bluestein R H & Co., Envestnet Asset Management Inc., Capital Guardian Trust Co. and O Shaughnessy Asset Management LLC.

Who bought Astrazeneca PLC stock? Who is buying Astrazeneca PLC stock?

Astrazeneca PLC's stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Allianz Asset Management AG, NWQ Investment Management Company LLC, Van ECK Associates Corp, Russell Investments Group Ltd., Dimensional Fund Advisors LP, Ellington Management Group LLC and Fred Alger Management Inc..

How do I buy Astrazeneca PLC stock?

Shares of Astrazeneca PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Astrazeneca PLC stock cost?

One share of Astrazeneca PLC stock can currently be purchased for approximately $28.92.

Astrazeneca PLC (NYSE:AZN) Chart for Thursday, February, 23, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Earnings History Chart

Earnings by Quarter for Astrazeneca PLC (NYSE:AZN)

Dividend History Chart

Dividend Payments by Quarter for Astrazeneca PLC (NYSE:AZN)

Last Updated on 2/23/2017 by Staff